Plavix and omeprazole
Pro Research Analysisby 
Searched over 200M research papers
Interaction Between Plavix (Clopidogrel) and Omeprazole: Clinical Implications
FDA Warning on Omeprazole and Clopidogrel Interaction
The US Food and Drug Administration (FDA) has issued a warning regarding the interaction between omeprazole (Prilosec) and clopidogrel (Plavix). According to the FDA, omeprazole can reduce the antiplatelet activity of clopidogrel by approximately 50%1. This reduction is primarily based on ex vivo data, which has raised concerns among clinicians about the potential impact on cardiovascular outcomes.
Clinical Trial Insights: No Significant Cardiovascular Impact
Despite the FDA warning, preliminary results from a randomized clinical trial have shown no significant effect on cardiovascular outcomes when omeprazole is co-administered with clopidogrel1. This finding suggests that the interaction may not be as clinically significant as initially feared. Consequently, it is recommended that physicians continue to prescribe proton pump inhibitors (PPIs) like omeprazole for patients on dual antiplatelet therapy who are at risk of gastrointestinal bleeding or have a clear indication for PPI use1.
Risk of Gastrointestinal Bleeding in High-Risk Patients
Patients who have undergone gastric bypass surgery and are taking clopidogrel are at a high risk of upper gastrointestinal bleeding. A study found that 36% of such patients experienced significant bleeding, which was managed by discontinuing clopidogrel and administering intravenous PPIs2. This highlights the importance of co-treatment with PPIs in high-risk groups to mitigate bleeding risks.
Reconsideration of PPI Use with Clopidogrel
Current guidelines recommend the use of PPIs to reduce the risk of gastrointestinal bleeding in patients taking clopidogrel and aspirin3. However, the potential interaction between omeprazole and clopidogrel has led to reconsideration of this practice. Until more definitive data is available, it is generally advised that patients continue their current regimen of clopidogrel and PPIs3.
Alternative PPIs: Pantoprazole as a Preferred Option
Not all PPIs have the same inhibitory effect on the enzyme CYP2C19, which is crucial for converting clopidogrel into its active form. The FDA specifically notes that the recommendation against the concomitant use of clopidogrel and omeprazole does not apply to all PPIs. Pantoprazole (Protonix) is considered a safer alternative as it is a weak inhibitor of CYP2C19 and has less impact on the pharmacological activity of clopidogrel4. For patients requiring both medications, pantoprazole may be the preferred choice4.
Conclusion
The interaction between omeprazole and clopidogrel has raised significant concerns, primarily due to FDA warnings and ex vivo data. However, clinical trial results suggest that the cardiovascular impact may not be substantial. For patients at high risk of gastrointestinal bleeding, the use of PPIs remains crucial. Pantoprazole is recommended as a safer alternative to omeprazole when co-administered with clopidogrel. Clinicians should continue to monitor emerging data to make informed decisions regarding the management of patients on dual antiplatelet therapy.
Sources and full results
Most relevant research papers on this topic
Omeprazole and clopidogrel: Should clinicians be worried?
Omeprazole reduces clopidogrel's antiplatelet activity by 50%, but a randomized clinical trial found no effect on cardiovascular outcomes when both drugs are used together.
Risk of massive upper gastrointestinal bleeding in gastric bypass patients taking clopidogrel.
Gastric bypass patients are at high risk of bleeding complications when taking clopidogrel, and co-treatment with omeprazole may be indicated when clopidogrel must be continued.
Observational StudyPPI interactions with clopidogrel revisited.
Patients taking both clopidogrel and proton pump inhibitors should continue to do so until more data is available on their interactions.
Coadministration of clopidogrel and proton pump inhibitors.
Pantoprazole is the preferred PPI for coadministering clopidogrel with a PPI, as it has less effect on Plavix's pharmacological activity than omeprazole.
Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management
Omeprazole can cause adverse drug interactions with various medications, requiring enhanced clinical risk management to avoid adverse consequences.
Systematic Review
Rigorous Journal
Highly CitedOmeprazole Administration in Preterm Preeclampsia: a Randomized Controlled Trial to Study Its Effect on sFlt-1 (Soluble Fms-Like Tyrosine Kinase-1), PlGF (Placental Growth Factor), and ET-1 (Endothelin-1)
Omeprazole does not alter circulating levels of sFlt-1, PlGF, or ET-1 in women with confirmed preeclampsia, suggesting its ineffectiveness as a treatment for this syndrome.
RCT
Very Rigorous JournalOmeprazole Increases the Efficacy of Acyclovir Against Herpes Simplex Virus Type 1 and 2
Omeprazole and other proton pump inhibitors enhance the anti-herpes simplex virus activity of acyclovir, making them potential candidates for antiviral therapies in combination with acyclovir.
In Vitro StudyEffects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults
Co-administration of GSK2336805 with omeprazole does not significantly impact its absorption and safety, suggesting no dose adjustment is needed when given together.
RCTVery Rigorous JournalOmeprazole administration does not impair gastrointestinal mucosal perfusion, oxygenation, and hexosamine generation.
Oral omeprazole, despite its antisecretory effect, has no adverse effect on gastrointestinal mucosal perfusion, oxygenation, or hexosamine generation in humans.
RCTOmeprazole Drug Interaction Studies
Omeprazole may partially inhibit the metabolism of drugs metabolized by cytochrome P450 subfamily IIC, but not those metabolized by subfamilies IA, IID, and IIIA.
Literature ReviewHighly Cited